Atherosclerosis-related biomarker PABPC1 predicts pan-cancer events

Miao Lin; Liubing Hu; Si Shen; Jiyue Liu; Yanyan Liu; Yixian Xu; Honglin Chen; Kazuo Sugimoto; Jianshuang Li; Ikuo Kamitsukasa; Takaki Hiwasa; Hao Wang; Anding Xu

doi:10.1136/svn-2022-002246

Atherosclerosis-related biomarker PABPC1 predicts pan-cancer events

Stroke Vasc Neurol. 2023 Jun 13:svn-2022-002246. doi: 10.1136/svn-2022-002246. Online ahead of print.

Authors

Miao Lin^#^{1

2}, Liubing Hu^#^{1

2

3}, Si Shen^#^{1

4}, Jiyue Liu^{1

2}, Yanyan Liu³, Yixian Xu^{1

2}, Honglin Chen^{1

4}, Kazuo Sugimoto^{5

6}, Jianshuang Li³, Ikuo Kamitsukasa^{7

8}, Takaki Hiwasa^{5

9}, Hao Wang^{10

2

5}, Anding Xu¹⁰

Affiliations

¹ Stroke Center, The First Affiliated Hospital, Jinan University, Guangzhou, China.
² Department of Anesthesiology, The First Affiliated Hospital, Jinan University, Guangzhou, China.
³ The Biomedical Translational Research Institute,Faculty of Medical Science, Jinan University, Guangzhou, China.
⁴ Department of Radiology, Medical Imaging Center, The First Affiliated Hospital, Jinan University, Guangzhou, China.
⁵ Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, Japan.
⁶ Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
⁷ Department of Neurology, Chiba Rosai Hospital, Chiba, Japan.
⁸ Department of Neurology, Chibaken Saiseikai Narashino Hospital, Chiba, Japan.
⁹ Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
¹⁰ Stroke Center, The First Affiliated Hospital, Jinan University, Guangzhou, China haowang@jnu.edu.cn tlil@jnu.edu.cn.

^# Contributed equally.

PMID: 37311641
DOI: 10.1136/svn-2022-002246

Abstract

Background: Atherosclerosis (AS) and tumours are the leading causes of death worldwide and share common risk factors, detection methods and molecular markers. Therefore, searching for serum markers shared by AS and tumours is beneficial to the early diagnosis of patients.

Methods: The sera of 23 patients with AS-related transient ischaemic attack were screened by serological identification of antigens through recombinant cDNA expression cloning (SEREX), and cDNA clones were identified. Pathway function enrichment analysis was performed on cDNA clones to identify their biological pathways and determine whether they were related to AS or tumours. Subsequently, gene-gene and protein-protein interactions were performed and AS-associated markers would be discovered. The expression of AS biomarkers in human normal organs and pan-cancer tumour tissues were explored. Then, immune infiltration level and tumour mutation burden of various immune cells were evaluated. Survival curves analysis could show the expression of AS markers in pan-cancer.

Results: AS-related sera were screened by SEREX, and 83 cDNA clones with high homology were obtained. Through functional enrichment analysis, it was found that their functions were closely related to AS and tumour functions. After multiple biological information interaction screening and the external cohort validating, poly(A) binding protein cytoplasmic 1 (PABPC1) was found to be a potential AS biomarker. To assess whether PABPC1 was related to pan-cancer, its expression in different tumour pathological stages and ages was screened. Since AS-associated proteins were closely related to cancer immune infiltration, we investigated and found that PABPC1 had the same role in pan-cancer. Finally, analysis of Kaplan-Meier survival curves revealed that high PABPC1 expression in pan-cancer was associated with high risk of death.

Conclusions: Through the findings of SEREX and bioinformatics pan-cancer analysis, we concluded that PABPC1 might serve as a potential biomarker for the prediction and diagnosis of AS and pan-cancer.

Keywords: Atherosclerosis; Cerebrovascular Disorders; Ischemic Attack, Transient; Stroke.